Paradoxical response to osimertinib therapy in a patient with T790M‑mutated lung adenocarcinoma
- Authors:
- Shinichiro Okauchi
- Hajime Osawa
- Kunihiko Miyazaki
- Mio Kawaguchi
- Hiroaki Satoh
View Affiliations
Affiliations: Division of Respiratory Medicine, Mito Medical Center, University of Tsukuba, Mito, Ibaraki 310‑0015, Japan, Division of Respiratory Medicine, Faculty of Medicine, University of Tsukuba, Tsukuba, Ibaraki 305‑8575, Japan
- Published online on: October 27, 2017 https://doi.org/10.3892/mco.2017.1474
-
Pages:
175-177
Metrics: Total
Views: 0 (Spandidos Publications: | PMC Statistics: )
Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )
This article is mentioned in:
Abstract
A ‘paradoxical response’ to cancer treatment is a term used to describe the emergence of unexpected new lesions and the progression of existing lesions, despite appropriate and effective therapy. ‘Pseudo‑progression’ is a phenomenon in which lymphocytes activated by an immune checkpoint inhibitor accumulate in a tumor and expand its shadow, mimicking enlargement of the primary lesion or development of a new metastatic lesion. Patients receiving cancer chemotherapy may respond differently to treatment, by exhibiting a response, deterioration, or the simultaneous occurrence of both. These variations may be attributed to the heterogeneity of the cancer. However, differences in the temporary response to epidermal growth factor receptor‑tyrosine kinase inhibitor (EGFR‑TKI) treatment are rarely observed. If such a phenomenon is observed, it should not affect the evaluation of the therapeutic effect or be considered as an indication for the discontinuation of treatment. We herein report a rare case of a transient increase in carcinomatous pleural fluid as a paradoxical response to osimertinib treatment in a patient with T790M‑mutated lung adenocarcinoma. The primary lesion and pulmonary metastases responded well to therapy. Although this paradoxical response is very rare, of non‑malignant nature, and does not usually require treatment modification of, physicians must acknowledge that it is not a clinically discouraging characteristic when using EGFR‑TKI to treat T790M‑mutated lung adenocarcinoma.
View References
|
1
|
Breen RA, Smith CJ, Bettinson H, Dart S,
Bannister B, Johnson MA and Lipman MC: Paradoxical reactions during
tuberculosis treatment in patients with and without HIV
co-infection. Thorax. 59:704–707. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Marshall BG and Chambers MA: Central
nervous system tuberculosis-the paradox of the host immune
response. J Infect. 36:3–4. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Gupta RC, Dixit R, Purohit SD and Saxena
A: Development of pleural effusion in patients during
anti-tuberculosis therapy: Analysis of twenty-nine cases with
review of literature. Indian J Chest Dis Allied Sci. 42:161–166.
2000.PubMed/NCBI
|
|
4
|
Bukharie H: Paradoxical response to
anti-tuberculosis drugs: Resolution with corticosteroid therapy.
Scand J Infect Dis. 32:96–97. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Al-Orainey IO: Diagnosis of latent
tuberculosis: Can we do better? Ann Thorac Med. 4:5–9. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Ito K, Hataji O, Katsuta K, Kobayashi T,
Gabazza EC, Yatabe Y, Taguchi O and Yamamoto N: ‘Pseudoprogression’
of pulmonary pleomorphic carcinoma during nivolumab therapy. J
Thorac Oncol. 11:e117–e119. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Kolla BC and Patel MR: Recurrent pleural
effusions and cardiac tamponade as possible manifestations of
pseudoprogression associated with nivolumab therapy- a report of
two cases. J Immunother Cancer. 4:802016. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Tanizaki J, Hayashi H, Kimura M, Tanaka K,
Takeda M, Shimizu S, Ito A and Nakagawa K: Report of two cases of
pseudoprogression in patients with non-small cell lung cancer
treated with nivolumab-including histological analysis of one case
after tumor regression. Lung Cancer. 102:44–48. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Di Giacomo AM, Danielli R, Guidoboni M,
Calabrò L, Carlucci D, Miracco C, Volterrani L, Mazzei MA, Biagioli
M, Altomonte M and Maio M: Therapeutic efficacy of ipilimumab, an
anti-CTLA-4 monoclonal antibody, in patients with metastatic
melanoma unresponsive to prior systemic treatments: Clinical and
immunological evidence from three patient cases. Cancer Immunol
Immunother. 58:1297–1306. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Hoos A, Parmiani G, Hege K, Sznol M,
Loibner H, Eggermont A, Urba W, Blumenstein B, Sacks N, Keilholz U,
et al: A clinical development paradigm for cancer vaccines and
related biologics. J Immunother. 30:1–15. 2007. View Article : Google Scholar : PubMed/NCBI
|
